AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	2424	51-34-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: scopolamine scopolamine hydrobromide hyoscine levo-duboisine scopoderm scopolamine hydrochloride scopolamine HCl	An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic. Molecular weight: 303.36 Formula: C17H21NO4 CLOGP: 0.09 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 62.30 ALOGS: -1.66 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

scopolamine
scopolamine hydrobromide
hyoscine
levo-duboisine
scopoderm
scopolamine hydrochloride
scopolamine HCl

An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic.

Molecular weight: 303.36
Formula: C17H21NO4
CLOGP: 0.09
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 62.30
ALOGS: -1.66
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.90	mg	O
0.90	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	666.67 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	6 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	27 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	3.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.50 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.513		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.832		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	22.491	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	8.204	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	88.840	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	88.770	%	High	1
herg	hERG pIC50	4.241	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	2.178	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.357	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	90.580	%	High	1
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1	20
kinase-selectivity-class	EIF2AK3	1
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	0.908		Moderate	0.73
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.239		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	57.280		High	1
mppb	Mouse plasma protein binding (% unbound)	90.380		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	6.266		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		Moderate	0.73
pppb	Pig plasma protein binding (% unbound)	94.340	%	High	1
rat-kpuu-brain	Rat brain Kpuu	0.058	%	Moderate	0.73
rh-clint	Rat hepatocyte intrinsic clearance	49.317	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	95.090	%	High	1
rppb	Rat plasma protein binding (% unbound)	81.080	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	944.061	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1979	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Swollen tongue	254.64	14.52	119	10568	45837	90571923
Dysphonia	230.14	14.52	123	10564	62961	90554799
Angioedema	221.34	14.52	121	10566	64755	90553005
Drug ineffective for unapproved indication	212.82	14.52	119	10568	66525	90551235
Swelling face	211.30	14.52	127	10560	81225	90536535
Anticholinergic syndrome	134.02	14.52	36	10651	2707	90615053
Mydriasis	118.93	14.52	50	10637	14962	90602798
Akathisia	71.48	14.52	32	10655	11127	90606633
Hypersensitivity	44.53	14.52	136	10551	454541	90163219
Differential white blood cell count abnormal	43.86	14.52	12	10675	966	90616794
Drug intolerance	40.24	14.52	130	10557	447461	90170299
Headache	40.16	14.52	204	10483	862542	89755218
High density lipoprotein decreased	39.55	14.52	14	10673	2637	90615123
Product adhesion issue	36.98	14.52	16	10671	5126	90612634
Neutrophil count increased	32.40	14.52	23	10664	19367	90598393
Arthropathy	32.26	14.52	3	10684	366239	90251521
Systemic lupus erythematosus	31.78	14.52	3	10684	361893	90255867
Off label use	30.00	14.52	227	10460	1102025	89515735
Vision blurred	27.74	14.52	48	10639	110245	90507515
Infectious mononucleosis	27.61	14.52	10	10677	2011	90615749
Joint swelling	26.71	14.52	13	10674	503287	90114473
Alopecia	25.95	14.52	13	10674	495058	90122702
Hallucination	25.46	14.52	35	10652	65924	90551836
Suicidal ideation	25.27	14.52	37	10650	73818	90543942
Application site rash	24.91	14.52	10	10677	2659	90615101
Musculoskeletal stiffness	24.65	14.52	3	10684	296529	90321231
Supraventricular tachycardia	24.16	14.52	18	10669	16318	90601442
Vomiting	24.06	14.52	167	10520	788126	89829634
Colitis	23.87	14.52	35	10652	69907	90547853
Progressive multiple sclerosis	23.83	14.52	8	10679	1286	90616474
Infusion related reaction	23.30	14.52	10	10677	416770	90200990
Red cell distribution width increased	21.61	14.52	15	10672	12192	90605568
Application site erythema	21.36	14.52	11	10676	5197	90612563
Tachyarrhythmia	20.97	14.52	11	10676	5395	90612365
Hyperkinesia	20.75	14.52	8	10679	1911	90615849
Agitation	20.65	14.52	32	10655	67066	90550694
Salivary hypersecretion	20.52	14.52	13	10674	9079	90608681
Abdominal discomfort	20.24	14.52	16	10671	477312	90140448
Somnolence	19.89	14.52	62	10625	209022	90408738
Tachycardia	19.10	14.52	51	10636	157622	90460138
Application site reaction	18.79	14.52	6	10681	824	90616936
Long QT syndrome congenital	18.73	14.52	4	10683	112	90617648
Blood lactic acid increased	18.45	14.52	12	10675	8766	90608994
Small intestinal obstruction	18.08	14.52	17	10670	21217	90596543
Impaired healing	17.99	14.52	3	10684	234196	90383564
Disorientation	17.92	14.52	24	10663	44090	90573670
Swelling	17.82	14.52	14	10673	419044	90198716
Nausea	17.65	14.52	204	10483	1110112	89507648
Cardiac output decreased	17.58	14.52	6	10681	1014	90616746
Patient elopement	17.07	14.52	4	10683	172	90617588
Rheumatoid arthritis	16.87	14.52	11	10676	362603	90255157
Urticaria	16.69	14.52	8	10679	312726	90305034
Emotional distress	16.53	14.52	21	10666	36641	90581119
Intra-abdominal haematoma	16.50	14.52	7	10680	2137	90615623
Constipation	16.39	14.52	71	10616	280324	90337436
Blood alkaline phosphatase increased	16.32	14.52	24	10663	48055	90569705
Wheezing	16.31	14.52	4	10683	238076	90379684
Seizure	16.15	14.52	47	10640	152582	90465178
Antipsychotic drug level above therapeutic	15.79	14.52	6	10681	1378	90616382
Hepatic enzyme increased	15.40	14.52	12	10675	360724	90257036
Psoriatic arthropathy	15.32	14.52	4	10683	228331	90389429
Dehydration	15.23	14.52	54	10633	194393	90423367
Arthralgia	14.82	14.52	45	10642	778477	89839283
Antipsychotic drug level below therapeutic	14.57	14.52	4	10683	326	90617434
Urine output decreased	14.56	14.52	12	10675	12591	90605169

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antipsychotic drug level increased	79.19	17.06	30	7379	4636	42609290
Neutrophil count increased	74.23	17.06	45	7364	19759	42594167
Prescription drug used without a prescription	70.67	17.06	24	7385	2706	42611220
Failure to suspend medication	65.62	17.06	15	7394	387	42613539
Neuroleptic malignant syndrome	53.99	17.06	38	7371	21434	42592492
White blood cell count increased	46.94	17.06	48	7361	45039	42568887
Differential white blood cell count abnormal	43.84	17.06	15	7394	1729	42612197
Antipsychotic drug level decreased	41.01	17.06	13	7396	1180	42612746
Ideas of reference	38.69	17.06	7	7402	52	42613874
Vomiting	37.55	17.06	123	7286	289600	42324326
Toxicity to various agents	36.90	17.06	105	7304	229031	42384895
Wrong patient received product	36.58	17.06	16	7393	3567	42610359
Accidental death	35.53	17.06	15	7394	3068	42610858
White blood cell count decreased	34.87	17.06	66	7343	110330	42503596
Mental impairment	33.78	17.06	23	7386	12294	42601632
Platelet count decreased	33.31	17.06	74	7335	138507	42475419
Confusional state	33.23	17.06	83	7326	167514	42446412
Salivary hypersecretion	31.36	17.06	21	7388	10922	42603004
Hallucination	31.28	17.06	44	7365	57463	42556463
Schizophrenia	29.64	17.06	20	7389	10530	42603396
Platelet count increased	29.38	17.06	20	7389	10683	42603243
Lymphocyte count decreased	27.83	17.06	29	7380	27780	42586146
Red blood cell elliptocytes present	27.80	17.06	6	7403	118	42613808
Pneumonia aspiration	26.76	17.06	38	7371	50040	42563886
Product adhesion issue	25.30	17.06	10	7399	1729	42612197
Incision site pain	24.43	17.06	10	7399	1893	42612033
Incorrect product dosage form administered	23.81	17.06	6	7403	236	42613690
Agitation	23.52	17.06	41	7368	64273	42549653
Tachycardia	23.17	17.06	53	7356	101034	42512892
Mydriasis	23.15	17.06	16	7393	8754	42605172
Neutrophil count decreased	22.63	17.06	40	7369	63375	42550551
Pneumoconiosis	22.49	17.06	6	7403	296	42613630
Drug ineffective	22.20	17.06	48	7361	630149	41983777
Seizure	22.09	17.06	58	7351	120503	42493423
Parkinsonian rest tremor	21.94	17.06	6	7403	325	42613601
Portal tract inflammation	21.76	17.06	5	7404	132	42613794
Constipation	21.04	17.06	69	7340	162222	42451704
Pupil fixed	21.00	17.06	9	7400	1908	42612018
Wrong technique in product usage process	20.81	17.06	31	7378	42604	42571322
Serotonin syndrome	20.73	17.06	24	7385	25821	42588105
Volvulus	20.58	17.06	9	7400	2004	42611922
Lung cancer metastatic	20.11	17.06	10	7399	2976	42610950
Haemoglobin decreased	19.63	17.06	59	7350	132412	42481514
Convulsive threshold lowered	19.32	17.06	6	7403	509	42613417
Mean cell volume decreased	18.89	17.06	8	7401	1647	42612279
Body temperature increased	18.20	17.06	20	7389	20338	42593588
Hallucination, auditory	17.63	17.06	17	7392	14847	42599079
Antipsychotic drug level above therapeutic	17.35	17.06	7	7402	1277	42612649
Hepatic steatosis	17.34	17.06	20	7389	21428	42592498

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Swollen tongue	210.84	15.03	122	15599	60240	110513338
Swelling face	195.60	15.03	136	15585	92185	110481393
Dysphonia	194.84	15.03	126	15595	75803	110497775
Angioedema	178.60	15.03	132	15589	98368	110475210
Drug ineffective for unapproved indication	158.26	15.03	125	15596	102713	110470865
Anticholinergic syndrome	115.64	15.03	37	15684	4243	110569335
Neutrophil count increased	112.93	15.03	67	15654	34585	110538993
Mydriasis	99.85	15.03	53	15668	22104	110551474
Antipsychotic drug level increased	80.02	15.03	32	15689	6983	110566595
Differential white blood cell count abnormal	75.33	15.03	23	15698	2261	110571317
Neuroleptic malignant syndrome	69.32	15.03	49	15672	34010	110539568
Akathisia	68.92	15.03	38	15683	17075	110556503
Failure to suspend medication	60.44	15.03	14	15707	472	110573106
White blood cell count increased	52.88	15.03	67	15654	96775	110476803
Vomiting	52.02	15.03	261	15460	910414	109663164
Hallucination	48.90	15.03	66	15655	101366	110472212
Hypersensitivity	44.20	15.03	142	15579	403856	110169722
White blood cell count decreased	39.32	15.03	95	15626	229295	110344283
Wrong patient received product	38.90	15.03	19	15702	6655	110566923
Lymphocyte count decreased	38.44	15.03	44	15677	57199	110516379
Seizure	38.33	15.03	92	15629	221093	110352485
Accidental death	37.66	15.03	17	15704	4992	110568586
Salivary hypersecretion	37.63	15.03	26	15695	17395	110556183
Agitation	36.50	15.03	61	15660	112990	110460588
High density lipoprotein decreased	35.47	15.03	17	15704	5716	110567862
Drug intolerance	35.00	15.03	132	15589	406380	110167198
Platelet count decreased	34.84	15.03	91	15630	230352	110343226
Antipsychotic drug level above therapeutic	34.46	15.03	13	15708	2427	110571151
Headache	34.02	15.03	228	15493	882149	109691429
Tachycardia	32.74	15.03	88	15633	226557	110347021
Neutrophil count decreased	32.24	15.03	60	15661	120881	110452697
Ideas of reference	31.71	15.03	7	15714	189	110573389
Mental impairment	31.56	15.03	26	15695	22613	110550965
Incision site pain	31.30	15.03	13	15708	3122	110570456
Constipation	30.64	15.03	116	15605	357670	110215908
Arthropathy	30.08	15.03	3	15718	287519	110286059
Joint swelling	29.53	15.03	13	15708	442832	110130746
Antipsychotic drug level decreased	29.29	15.03	10	15711	1402	110572176
Arthralgia	29.21	15.03	41	15680	779591	109793987
Musculoskeletal stiffness	29.07	15.03	3	15718	279819	110293759
Pneumonia aspiration	27.79	15.03	45	15676	81188	110492390
Red blood cell elliptocytes present	26.58	15.03	6	15715	180	110573398
Dyskinesia	25.58	15.03	34	15687	51412	110522166
Dehydration	25.06	15.03	92	15629	279419	110294159
Liver function test abnormal	24.69	15.03	39	15682	68911	110504667
Platelet count increased	24.35	15.03	24	15697	26310	110547268
Somnolence	24.27	15.03	95	15626	297354	110276224
Alopecia	23.85	15.03	11	15710	364742	110208836
Volvulus	23.50	15.03	11	15710	3507	110570071
Pneumoconiosis	23.30	15.03	6	15715	316	110573262
Eosinophil count decreased	23.23	15.03	13	15708	6005	110567573
Incorrect product dosage form administered	23.03	15.03	6	15715	331	110573247
Rheumatoid arthritis	22.99	15.03	7	15714	299606	110273972
Infusion related reaction	22.68	15.03	13	15708	381149	110192429
Abdominal discomfort	22.64	15.03	14	15707	393844	110179734
Haemoglobin decreased	22.41	15.03	82	15639	248645	110324933
Confusional state	22.32	15.03	128	15593	468552	110105026
Swelling	22.32	15.03	11	15710	351030	110222548
Progressive multiple sclerosis	22.19	15.03	8	15713	1316	110572262
Glossodynia	21.53	15.03	3	15718	222001	110351577
Application site erythema	21.34	15.03	12	15709	5598	110567980
Blood alkaline phosphatase increased	21.21	15.03	37	15684	70898	110502680
Intestinal obstruction	20.30	15.03	31	15690	53196	110520382
Convulsive threshold lowered	20.11	15.03	7	15714	1039	110572539
Portal tract inflammation	19.83	15.03	5	15716	242	110573336
Wheezing	19.51	15.03	6	15715	255224	110318354
Serotonin syndrome	19.19	15.03	32	15689	59121	110514457
Hepatic enzyme increased	19.01	15.03	11	15710	320881	110252697
Death	18.71	15.03	166	15555	698703	109874875
Fatigue	18.30	15.03	100	15621	1215858	109357720
Red cell distribution width increased	18.08	15.03	17	15704	17585	110555993
Cholelithiasis	17.57	15.03	32	15689	63390	110510188
Muscle rigidity	17.03	15.03	19	15702	24012	110549566
Antipsychotic drug level below therapeutic	16.67	15.03	7	15714	1728	110571850
Electrocardiogram QT prolonged	16.42	15.03	43	15678	108917	110464661
Long QT syndrome congenital	16.35	15.03	4	15717	171	110573407
Psoriatic arthropathy	16.21	15.03	4	15717	196757	110376821
Lung cancer metastatic	16.02	15.03	9	15712	4189	110569389
Mean cell volume decreased	15.94	15.03	10	15711	5692	110567886
Therapeutic product effect incomplete	15.83	15.03	6	15715	223799	110349779
Mental status changes	15.76	15.03	34	15687	76088	110497490
Weight increased	15.76	15.03	22	15699	419622	110153956
Apnoea	15.62	15.03	14	15707	13625	110559953
Hallucination, auditory	15.58	15.03	19	15702	26378	110547200
Hyperkinesia	15.43	15.03	8	15713	3176	110570402
Intentional product use issue	15.40	15.03	8	15713	247898	110325680
Hepatic steatosis	15.29	15.03	26	15695	48805	110524773
Product administered to patient of inappropriate age	15.06	15.03	11	15710	8025	110565553
Fibromyalgia	15.04	15.03	3	15718	170906	110402672

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A04AD01	ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics
ATC	A04AD51	ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics
ATC	N05CM05	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Other hypnotics and sedatives
ATC	S01FA02	SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D000932	Antiemetics
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D009184	Mydriatics
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
CHEBI has role	CHEBI:25212	metabolite
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:48876	muscarinic antagonist
CHEBI has role	CHEBI:50513	mydriatic agent
CHEBI has role	CHEBI:50919	antiemetic
CHEBI has role	CHEBI:53784	antispasmodic drug
CHEBI has role	CHEBI:60807	anaesthesia adjuvant
CHEBI has role	CHEBI:60809	adjuvant
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:35480	analgesic

Related Drugs by ATC class:

A04AD Other antiemetics 8 drugs

aprepitant casopitant cerium oxalate chlorobutanol dronabinol metopimazine nabilone rolapitant

N05CM Other hypnotics and sedatives 13 drugs

apronal bromisoval carbromal clomethiazole dexmedetomidine ethchlorvynol hexapropymate methaqualone methylpentynol niaprazine propiomazine triclofos show all 13 →

S01FA Anticholinergics 5 drugs

atropine cyclopentolate homatropine methscopolamine tropicamide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Irritable bowel syndrome	indication	10743008	DOID:9778
Peptic ulcer	indication	13200003	DOID:750
Prevention of motion sickness	indication	37031009	DOID:2951
Motion sickness	indication	37031009	DOID:2951
Dilated pupil	indication	37125009
Cough	indication	49727002
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Cycloplegia	indication	68158006	DOID:10033
Nasal congestion	indication	68235000
Iridocyclitis	indication	77971008
Common cold	indication	82272006	DOID:10459
Posterior synechiae	indication	111512005
Uveitis	indication	128473001	DOID:13141
Prevention of Posterior Synechiae	indication
Prevention of Post-Operative Nausea and Vomiting	indication
Perioperative Mydriasis	indication
General anesthesia	off-label use	50697003
Excessive salivation	off-label use	53827007
Rhinitis	off-label use	70076002	DOID:4483
Seasonal allergic rhinitis	off-label use	367498001
Brain damage	contraindication	2470005
Ocular hypertension	contraindication	4210003	DOID:9282
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Hyperammonemia	contraindication	9360008
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Hepatic encephalopathy	contraindication	13920009	DOID:13413
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Disorder of lung	contraindication	19829001	DOID:850
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Ventricular tachycardia	contraindication	25569003
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Acute hepatitis	contraindication	37871000
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypovolemic shock	contraindication	39419009
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Hyperactive behavior	contraindication	44548000
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Acidosis	contraindication	51387008
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Paralytic ileus	contraindication	55525008	DOID:8442
Heart disease	contraindication	56265001	DOID:114
Peptic reflux disease	contraindication	57643001
Hepatic failure	contraindication	59927004
Ulcerative colitis	contraindication	64766004	DOID:8577
Poisoning by phenobarbital	contraindication	64921004
Arterial thrombosis	contraindication	65198009
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Arteriosclerotic vascular disease	contraindication	72092001
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Sleep apnea	contraindication	73430006	DOID:0050847
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Chronic idiopathic constipation	contraindication	82934008
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Magnetic resonance imaging	contraindication	113091000
Hypoalbuminemia	contraindication	119247004
Gastrointestinal obstruction	contraindication	126765001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Partial atrioventricular block	contraindication	195039008
Acute pancreatitis	contraindication	197456007	DOID:2913
Myocardial dysfunction	contraindication	233928007
Arterial aneurysm	contraindication	233981004
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Dyspnea	contraindication	267036007
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Severe chronic obstructive pulmonary disease	contraindication	313299006
Hypoxia	contraindication	389086002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Porphyria	contraindication	418470004
Fever greater than 100.4 Fahrenheit	contraindication	426000000
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.24	acidic
pKa2	7.95	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9	WOMBAT-PK	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	9.37	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	8.86	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.75	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	9.40	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Kd	8.52	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	9.28	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Kd	9.19	CHEMBL
Muscarinic receptor M1	GPCR		Q8WMX0_BOVIN		Ki	9.39	CHEMBL
Muscarinic acetylcholine receptor DM1	GPCR		ACM1_DROME		Ki	9.15	CHEMBL
Muscarinic acetylcholine receptor	GPCR		ACM1_RAT ACM3_RAT ACM4_RAT ACM5_RAT ACM2_RAT		Ki	10.10	CHEMBL

External reference:

ID	Source
4018401	VUID
N0000146728	NUI
D00138	KEGG_DRUG
6533-68-2	SECONDARY_CAS_RN
4018399	VANDF
4018401	VANDF
4018412	VANDF
C0036442	UMLSCUI
CHEBI:16794	CHEBI
CHEMBL569713	ChEMBL_ID
CHEMBL2251240	ChEMBL_ID
DB00747	DRUGBANK_ID
D012601	MESH_DESCRIPTOR_UI
3000322	PUBCHEM_CID
330	IUPHAR_LIGAND_ID
55-16-3	SECONDARY_CAS_RN
DL48G20X8X	UNII
9601	RXNORM
1472	MMSL
5444	MMSL
5445	MMSL
72365	MMSL
d00986	MMSL
001719	NDDF
003458	NDDF
387409009	SNOMEDCT_US
387477005	SNOMEDCT_US
72870001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Scopolamine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6470	PATCH	1 mg	TRANSDERMAL	ANDA	31 sections
Belladonna Alkaloids with Phenobartbital	HUMAN PRESCRIPTION DRUG LABEL	4	0440-7183	TABLET	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
scopolamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2258	SYSTEM	1 mg	TRANSDERMAL	ANDA	28 sections
Transderm Scop	HUMAN PRESCRIPTION DRUG LABEL	1	10019-008	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	NDA	29 sections
Transderm Scop	HUMAN PRESCRIPTION DRUG LABEL	1	10019-553	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	NDA	29 sections
Phenohytro	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0123	ELIXIR	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
Phenohytro	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0125	ELIXIR	0.01 mg	ORAL	unapproved drug other	19 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0162	ELIXIR	0.01 mg	ORAL	unapproved drug other	16 sections
Donnatal	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0423	ELIXIR	0.01 mg	ORAL	unapproved drug other	12 sections
RE-PB HYOS ELIXIR	HUMAN PRESCRIPTION DRUG LABEL	4	21695-594	ELIXIR	0.01 mg	ORAL	Unapproved drug other	11 sections
Belladonna Alkaloids with Phenobartbital	HUMAN PRESCRIPTION DRUG LABEL	4	21695-890	TABLET	0.01 mg	ORAL	Unapproved drug other	15 sections
QUADRAPAX	HUMAN PRESCRIPTION DRUG LABEL	4	21695-970	ELIXIR	0.01 mg	ORAL	Unapproved drug other	13 sections
Donnatal	HUMAN PRESCRIPTION DRUG LABEL	4	42254-268	TABLET	0.01 mg	ORAL	Unapproved drug other	15 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS	HUMAN PRESCRIPTION DRUG LABEL	4	42291-205	ELIXIR	0.01 mg	ORAL	unapproved drug other	17 sections
Scopolamine	HUMAN PRESCRIPTION DRUG LABEL	1	42858-150	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	ANDA	33 sections
Scopolamine Transdermal System	HUMAN PRESCRIPTION DRUG LABEL	1	45802-580	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	ANDA	30 sections
Scopolamine Transdermal System	HUMAN PRESCRIPTION DRUG LABEL	1	45802-580	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	ANDA	30 sections
Scopolamine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5349	PATCH	1 mg	TRANSDERMAL	ANDA	30 sections
scopolamine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7188	SYSTEM	1 mg	TRANSDERMAL	ANDA	27 sections
Scopolamine	HUMAN PRESCRIPTION DRUG LABEL	1	50742-505	PATCH, EXTENDED RELEASE	1.50 mg	TRANSDERMAL	ANDA	32 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide	Human Prescription Drug Label	4	50742-665	ELIXIR	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide	Human Prescription Drug Label	4	50742-666	ELIXIR	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide	Human Prescription Drug Label	4	50742-667	TABLET	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	20 sections
Transderm Scop	HUMAN PRESCRIPTION DRUG LABEL	1	54868-2803	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	NDA	24 sections
Donnatal	Human Prescription Drug Label	4	59212-422	ELIXIR	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	22 sections
Donnatal	Human Prescription Drug Label	4	59212-423	ELIXIR	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	22 sections
Donnatal	Human Prescription Drug Label	4	59212-425	TABLET	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	22 sections
Scopolamine Trandermal System	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8450	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	ANDA	30 sections
Scopolamine Trandermal System	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8451	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	ANDA	30 sections
Scopolamine Trandermal System	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8452	PATCH, EXTENDED RELEASE	1 mg	TRANSDERMAL	ANDA	30 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

scopolamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: